{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:30:25Z","timestamp":1783434625111,"version":"3.54.6"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["U01 CA176067-01A1"],"award-info":[{"award-number":["U01 CA176067-01A1"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["CA-16359"],"award-info":[{"award-number":["CA-16359"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006349","name":"Deborah Bunn Alley Ovarian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006800","name":"Honorable Tina Brozman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006800","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012175","name":"Discovery To Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006696","name":"Fondazione Guido Berlucchi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Datopotamab deruxtecan (Dato-DXd) is a novel antibody\u2013drug conjugate (ADC) targeting trophoblast antigen-2 (TROP2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver DXd, a potent topoisomerase I inhibitor. We evaluated TROP2 expression in primary endometrial cancer cell lines and the activity of Dato-DXd against endometrial cancer cell lines with different TROP2 expression in vitro and in vivo. TROP2 expression was assessed in nine primary tumor cell lines by flow cytometry. Cell viability after exposure to Dato-DXd was evaluated using flow cytometry\u2013based assays to calculate the IC50. Bystander effect assay assessed the viability of TROP2-negative cells when cocultured with high TROP2-expressing cells. Fluorescent anti\u2013phosphorylated histone H2AX antibody was used to demonstrate double-strand DNA breaks. Antibody-dependent cell cytotoxicity was tested in vitro using 4-hour chromium release assays. In vivo activity of Dato-DXd was evaluated against TROP2-positive endometrial cancer xenografts. A total of 78% (seven of nine) of the primary endometrial cancer cell lines expressed TROP2. Endometrial cancer cell lines expressing TROP2 were significantly more sensitive to Dato-DXd compared with control ADC. Dato-DXd\u2013exposed, TROP2-positive endometrial cancer demonstrated increased double-strand DNA breaks compared with non-binding conjugate exposure. Dato-DXd mediated antibody-dependent cell cytotoxicity against TROP2-positive cell lines and induced significant bystander killing of TROP2-negative tumors when admixed with TROP2-positive tumors. In vivo, injection of Dato-DXd was well tolerated and demonstrated impressive tumor growth inhibition against chemotherapy-resistant poorly differentiated endometrial cancer xenografts (P &amp;lt; 0.0001). In conclusion, Dato-DXd is a novel ADC with remarkable preclinical activity against poorly differentiated endometrial cancer cell lines overexpressing TROP2. Clinical trials with Dato-DXd in patients with recurrent endometrial cancer are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Targeted treatment of aggressive forms of endometrial cancer using the biomarker TROP2 is a significant opportunity for the development of treatments when patients are resistant to other lines of treatment. Here, we present data showing preclinical evidence of effectiveness of this biomarker-targeted therapy in endometrial cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0251","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:31:52Z","timestamp":1756297912000},"page":"1611-1620","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody\u2013Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2669-0973","authenticated-orcid":false,"given":"Niccol\u00f2 G.","family":"Santin","sequence":"first","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."},{"name":"2Humanitas Hospital San Pio X, Humanitas University, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-3338","authenticated-orcid":false,"given":"Namrata","family":"Sethi","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5909-5292","authenticated-orcid":false,"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-2819","authenticated-orcid":false,"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-2534","authenticated-orcid":false,"given":"Victoria M.","family":"Ettorre","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-1468","authenticated-orcid":false,"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-218X","authenticated-orcid":false,"given":"Blair","family":"McNamara","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-334X","authenticated-orcid":false,"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-2894","authenticated-orcid":false,"given":"Tobias M.P.","family":"Hartwich","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-3300","authenticated-orcid":false,"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."},{"name":"4Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[{"name":"2Humanitas Hospital San Pio X, Humanitas University, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-9738","authenticated-orcid":false,"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2025091103550413300_bib1","article-title":"Endomerial cancer statistics","author":"World Cancer Research Fund","year":"2025"},{"key":"2025091103550413300_bib2","article-title":"Key statistics for endometrial cancer","author":"American Cancer Society","year":"2025"},{"key":"2025091103550413300_bib3","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025091103550413300_bib4","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2025091103550413300_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"2025091103550413300_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"2025091103550413300_bib7","article-title":"Endometrial cancer treatment (PDQ)-Health professional version","author":"National Cancer Institute","year":"2025"},{"key":"2025091103550413300_bib8","article-title":"Survival rates for endometrial cancer","author":"American Cancer Society","year":"2025"},{"key":"2025091103550413300_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/IGC.0000000000000891","article-title":"Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma","volume":"27","author":"Rose","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"2025091103550413300_bib10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0360-3016(01)01765-5","article-title":"The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial","volume":"51","author":"Creutzberg","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025091103550413300_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/IGC.0000000000000376","article-title":"Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics","volume":"25","author":"Young","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"2025091103550413300_bib12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00280-015-2861-1","article-title":"Targeted therapy in cancer","volume":"76","author":"Tsimberidou","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025091103550413300_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"2025091103550413300_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6890-12-22","article-title":"Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma","volume":"12","author":"Bignotti","year":"2012","journal-title":"BMC Clin Pathol"},{"key":"2025091103550413300_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"2025091103550413300_bib16","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025091103550413300_bib17","doi-asserted-by":"crossref","first-page":"e28385","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"key":"2025091103550413300_bib18","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025091103550413300_bib19","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091103550413300_bib20","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2212 and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091103550413300_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025091103550413300_bib22","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study","volume":"35","author":"Oaknin","year":"2024","journal-title":"Ann Oncol"},{"key":"2025091103550413300_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.bjc.6605448","article-title":"In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma","volume":"102","author":"El-Sahwi","year":"2010","journal-title":"Br J Cancer"},{"key":"2025091103550413300_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10585-013-9614-5","article-title":"Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin\/paclitaxel","volume":"31","author":"Roque","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"2025091103550413300_bib25","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025091103550413300_bib26","doi-asserted-by":"crossref","first-page":"e70210","DOI":"10.1002\/cam4.70210","article-title":"Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer","volume":"13","author":"Hartwich","year":"2024","journal-title":"Cancer Med"},{"key":"2025091103550413300_bib27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol Oncol"},{"key":"2025091103550413300_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2008.08.037","article-title":"Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer","volume":"274","author":"Liu","year":"2009","journal-title":"Cancer Lett"},{"key":"2025091103550413300_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.20408","article-title":"Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy","volume":"112","author":"Santin","year":"2004","journal-title":"Int J Cancer"},{"key":"2025091103550413300_bib30","doi-asserted-by":"crossref","first-page":"567.e1\u20137","DOI":"10.1016\/j.ajog.2011.06.093","article-title":"Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody","volume":"205","author":"Varughese","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"2025091103550413300_bib31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/CMAR.S147033","article-title":"Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas","volume":"9","author":"Xu","year":"2017","journal-title":"Cancer Manag Res"},{"key":"2025091103550413300_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1158\/2767-9764.CRC-25-0057","article-title":"Preclinical activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, in uterine serous carcinoma","volume":"5","author":"Greenman","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2025091103550413300_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2024.07.002","article-title":"Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma","volume":"189","author":"McNamara","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025091103550413300_bib34","article-title":"FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer","author":"FDA","year":"2025"},{"key":"2025091103550413300_bib35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"key":"2025091103550413300_bib36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"2025091103550413300_bib37","article-title":"FDA approves sacituzumab govitecan-hziy for pretreated patients with HR-positive, HER2-negative breast cancer","author":"The ASCO Post","year":"2023"},{"key":"2025091103550413300_bib38","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2217\/fon-2022-0407","article-title":"Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon","volume":"18","author":"Furlanetto","year":"2022","journal-title":"Future Oncol"},{"key":"2025091103550413300_bib39","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091103550413300_bib40","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3390\/pharmaceutics14081707","article-title":"The potential of topoisomerase inhibitor-based antibody-drug conjugates","volume":"14","author":"Han","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0251\/3646405\/crc-25-0251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1611\/3650654\/crc-25-0251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1611\/3650654\/crc-25-0251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:55:13Z","timestamp":1757577313000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1611\/765111\/Preclinical-Activity-of-Datopotamab-Deruxtecan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0251","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30102515","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30102503","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30102506","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30102500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30102521","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30102512","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30102518","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30102509","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8028839","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}